Frontotemporal dementia associated with the C9ORF72 mutation: A unique clinical profile

JAMA Neurology

Volumn 71, Issue 3, 2014, Pages 331-339

  Devenney, Emma ^a,b   Hornberger, Michael ^b,c   Irish, Muireann ^b,c   Mioshi, Eneida ^b,c   Burrell, James ^b,c   Tan, Rachel ^b,c   Kiernan, Matthew C ^b,d   Hodges, John R ^b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN ATROPHY; C9ORF72 GENE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FAMILY HISTORY; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUTATION RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS;

AMYOTROPHIC LATERAL SCLEROSIS; ATROPHY; DISEASE PROGRESSION; FRONTOTEMPORAL DEMENTIA; GENETIC VARIATION; HUMANS; MUTATION; PROSPECTIVE STUDIES; PROTEINS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 84896781404     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.6002     Document Type: Article

References (44)

1. Renton AE, Majounie E, Waite A, et al; ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72(2): 257-268.
2. Hsiung GY, DeJesus-Hernandez M, Feldman HH, et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain. 2012; 135(pt 3): 709-722.
3. Majounie E, Renton AE, Mok K, et al; Chromosome 9-ALS/FTD Consortium; French Research Network on FTLD/FTLD/ALS; ITALSGEN Consortium. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012; 11(4): 323-330.
4. Simón-Sánchez J, Dopper EG, Cohn-Hokke PE, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012; 135(pt 3): 723-735.
5. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012; 11(3): 232-240.
6. Chiò A, Borghero G, Restagno G, et al; ITALSGEN consortium. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012; 135(pt 3): 784-793.
7. Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012; 135(pt 3): 765-783.
8. Van Langenhove T, van der Zee J, Gijselinck I, et al. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol. 2013; 70(3): 365-373.
9. Mahoney CJ, Downey LE, Ridgway GR, et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther. 2012; 4(5): 41.
10. Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012; 135(pt 3): 693-708.
11. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain. 2012; 135(pt 3): 736-750.
12. Sha SJ, Takada LT, Rankin KP, et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology. 2012; 79(10): 1002-1011.
13. Irwin DJ, McMillan CT, Brettschneider J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013; 84(2): 163-169.
14. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012; 135(pt 3): 794-806.
15. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134(pt 9): 2456-2477.
16. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011; 76(11): 1006-1014.
17. Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome: a comparative study. J Neurol Neurosurg Psychiatry. 2012; 83(4): 405-410.
18. Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005; 65(11): 1817-1819.
19. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination-Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006; 21(11): 1078-1085.
20. Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR. Clinical staging and disease progression in frontotemporal dementia. Neurology. 2010; 74(20): 1591-1597.
21. Wedderburn C, Wear H, Brown J, et al. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry. 2008; 79(5): 500-503.
22. Meyers J, Meyers K. The Meyers Scoring System for the Rey Complex Figure and the Recognition Trial: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1995.
23. Warrington EK, James M. The Visual Object and Space Perception Battery. Bury St Edmunds, England: Thames Valley Test Co; 1991.
24. Schmidt M. Rey Auditory Verbal Learning Test: A Handbook. Los Angeles, CA: Western Psychological Services; 1996.
25. Burgess PW, Shallice T. Response suppression, initiation and strategy use following frontal lobe lesions. Neuropsychologia. 1996; 34(4): 263-272.
26. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York, NY: Oxford University Press; 1998.
27. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958; 8(3): 271-276. doi:10.2466/pms.1958.8.3. 271.
28. Savage S, Hsieh S, Leslie F, Foxe D, Piguet O, Hodges JR. Distinguishing subtypes in primary progressive aphasia: application of the Sydney Language Battery. Dement Geriatr Cogn Disord. 2013; 35(3-4): 208-218.
29. Bishop DV. Test for Reception of Grammar: TROG-2 Version 2. London, England: Pearson Education; 2003.
30. Kipps CM, Davies RR, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord. 2007; 23(5): 334-342.
31. Davies RR, Scahill VL, Graham A, Williams GB, Graham KS, Hodges JR. Development of an MRI rating scale for multiple brain regions: comparison with volumetrics and with voxel-based morphometry. Neuroradiology. 2009; 51(8): 491-503.
32. Dobson-Stone C, Hallupp M, Bartley L, et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology. 2012; 79(10): 995-1001.
33. Byrne S, Heverin M, Elamin M, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis [published online July 9, 2013]. Ann Neurol. doi:10.1002/ana.23969.
34. Beck J, Poulter M, Hensman D, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013; 92(3): 345-353.
35. Lesage S, Le Ber I, Condroyer C, et al; French Parkinson's Disease Genetics Study Group. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain. 2013; 136(pt 2): 385-391.
36. Lillo P, Garcin B, Hornberger M, Bak TH, Hodges JR. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. 2010; 67(7): 826-830.
37. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011; 377(9769): 942-955.
38. Loy CT, Kril JJ, Trollor JN, et al. The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol. 2010; 6(3): 175-179.
39. Irish M, Devenney E, Wong S, et al. Neural substrates of episodic memory dysfunction in behavioural variant frontotemporal dementia with and without C9ORF72 expansions. Neuroimage Clin. 2013; 2: 836-843.
40. Khan BK, Yokoyama JS, Takada LT, et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry. 2012; 83(4): 358-364.
41. Davies RR, Kipps CM, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol. 2006; 63(11): 1627-1631.
42. Hornberger M, Shelley BP, Kipps CM, Piguet O, Hodges JR. Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation? J Neurol Neurosurg Psychiatry. 2009; 80(6): 591-593.
43. Hornberger M, Piguet O, Kipps C, Hodges JR. Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia. Neurology. 2008; 71(19): 1481-1488.
44. Mioshi E, Hodges JR. Rate of change of functional abilities in frontotemporal dementia. Dement Geriatr Cogn Disord. 2009; 28(5): 419-426.